neoplasm, nasopharyngeal malignant neoplasm, piriform sinus malignant neoplasm, hypopharynx malignant neoplasm;

esophagus malignant neoplasm, gastric malignant neoplasm, small intestine malignant neoplasm, colon malignant neoplasm, rectosigmoid junction malignant neoplasm, rectal malignant neoplasm, anal and anal canal malignant neoplasm, liver and intrahepatic bile duct malignant neoplasm, gallbladder malignant neoplasm, pancreatic malignant neoplasm;

nasal and middle ear malignant neoplasm, nasal sinus malignant neoplasm, laryngeal malignant neoplasm, tracheal malignant neoplasm, bronchial and pulmonary malignant neoplasm, thymus malignant neoplasm, heart, mediastinal and pleural malignant neoplasm;

bone and articular cartilage malignant neoplasm;

skin malignant melanoma;

mesothelial and soft tissue malignant neoplasm;

breast malignant neoplasm;

genital malignant neoplasm, vaginal malignant neoplasm, cervical malignant neoplasm, uterine malignant neoplasm, ovarian malignant neoplasm, placental malignant neoplasm;

penile malignant neoplasm, prostate malignant neoplasm, testicular malignant neoplasm;

urinary tract malignant neoplasm;

eye and appendage malignant neoplasm;

meningeal malignant neoplasm, brain malignant neoplasm;

spinal cord, cranial nerve and central nervous system malignant neoplasm;

endocrine gland malignant neoplasm;

Hodgkin's disease, follicular nodular non-Hodgkin's lymphoma, diffuse non-Hodgkin's lymphoma, peripheral and cutaneous T-cell lymphoma, multiple myeloma, malignant plasma cell tumor, lymphoid leukemia, myeloid leukemia, monocytic leukemia.

17. The use according to claim 15, wherein, when the composition according to any of claims 1-14 contains a virus, the cancer is not caused by the virus.

18. Use according to claim 15, wherein the medicament is to be administeredto a subject.

19. Theuse according to claim 18, wherein the route of said administration is selected from the group consisting of intramuscular, intraperitoneal, intravenous, subcutaneous, transdermal, intradermal, intranasal, intraocular, oral, sublingual, intratumoral, and peritumoral.

20. The use according to claim 18, wherein said administration is to be at a frequency selected from the group consisting of once per month, 2 times per month, 3 times per month, 4 times per month, 5 times per month, 6 times per month, 7 times per month, 8 times per month, once per week, 2 times per week, 3 times per week, 4 times per week, 5 times per week, 6 times per week, once every three days, 2 times every three days, 3 times every three days, once every two days, 2 times every two days, once per day, 2 times per day.

21. The use according to claim 18, wherein

a therapeutically effective amount of the composition of claim 14 is to be administered to a human subject through intramuscular injection at a frequency of 2 times every three days, or

a therapeutically effective amount of the composition of claim 14 is to be administered to a human subject through intramuscular injection at a frequency of once per week.

22. The use according to claim 18, wherein said cancer is selected from the group consisting of lung cancer, breast cancer, thyroid cancer, kidney cancer, gastric adenocarcinoma, liver cancer, melanoma, tongue cancer, rectal cancer, endometrial cancer, and ovarian cancer; more preferably said cancer is a metastatic tumor.

23. Use of the composition according to any one of claims 1-14 in combination with an anti-tumor treatment regimen in manufacture of a medicament for treatment of cancer;

preferably, said anti-tumor treatment regimen is selected from the group consisting of chemotherapy, radiotherapy, targeted therapy, and immunotherapy, wherein the therapeutical agent used in said chemotherapy is selected from the group consisting of alkylating agent, anti-metabolic antineoplastic agent, anti-tumor antibiotic, anti-tumor botanical, platinum